SARS News and Research

RSS

Comparison of Pfizer, Moderna, J&J, AZ vaccines for neutralization titer, against Delta and other variants

Is one COVID vaccine better than the other? Four current vaccines — Moderna, Pfizer-BioNTech, Johnson & Johnson, and AstraZeneca — are highly effective against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), but a new medRxiv* study suggests the level of protection varies.

30 Sep 2021

New approach reveals ‘protein partners’ that may contribute to unusual pathologies of COVID-19

COVID-19 not only causes symptoms characteristic of a typical respiratory disorder, but has also been known to trigger a wide range of other symptoms in people who had been infected, some lasting even long after individuals test negative for the virus.

30 Sep 2021

Moderna vaccine reduced viral load and protected against SARS-CoV-2 variants in new phase 3 trial

Coronavirus research has shown that higher viral loads are associated with severe COVID-19 infection. But new results from the phase III Coronavirus Efficacy (COVE) clinical trial find the Moderna vaccine reduces severe acute respiratory coronavirus 2 (SARS-CoV-2) viral load and viral shedding.

30 Sep 2021

Non-severe COVID-19 may elicit more durable memory B cell response than severe COVID-19

A recent study conducted by researchers from the US aimed to measure the impact of severity of COVID-19 on memory B cell response and characterize changes in the memory B cell compartment during the period between recovery and five months after symptom onset. This study is available on the bioRxiv* preprint server.

30 Sep 2021

University of Oxford and Oracle's Global Pathogen Analysis System helping researchers to combat COVID-19

The fast spread of the highly infectious Delta variant underscores the need for faster identification of COVID-19 mutations. Uniting governments and medical communities in this challenge, the University of Oxford and Oracle's Global Pathogen Analysis System (GPAS) is now being used by organizations on nearly every continent.

30 Sep 2021

Early-stage interaction of monocytes with SARS-CoV-2-infected epithelial cell decides COVID-19 severity

A team of scientists from the USA and France has recently unveiled the mechanism of immune dysregulation in coronavirus disease 2019 (COVID-19) patients by analyzing the early-stage interaction between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-infected epithelial cells and immune cells. The study is currently available on the bioRxiv* preprint server.

30 Sep 2021

Pediatric transplant recipients mount a more robust immune response after two COVID-19 vaccine doses

In a study published today in the American Journal of Transplantation, Johns Hopkins Medicine researchers say that children between the ages of 12 and 18 who have received solid organ transplants appear to mount a more robust immune response than their adult counterparts after a standard two-dose vaccination regimen against SARS-CoV-2, the virus that causes COVID-19.

30 Sep 2021

Rise of the Delta variant increases COVID-19 hospitalizations among unvaccinated pregnant women

Unvaccinated pregnant women are increasingly being hospitalized with COVID-19 during a nationwide surge of the Delta variant, according to research from UT Southwestern Medical Center.

30 Sep 2021

The connection between age and virulence of SARS-CoV-2 variants of concern

A new study focuses on determining the existence of an age-related heterogeneity in the severity of COVID-19.

30 Sep 2021

SARS-CoV-2 nucleocapsid antigen as a possible COVID-19 severity marker

French researchers used a highly sensitive and specific nucleocapsid-Ag assay to explore the relationship between N-Ag in urine during COVID-19 and the severity of the disease in hospitalized patients.

30 Sep 2021

New drug combination effectively suppresses SARS-CoV-2 infection

More countries with greater resources are opening up for a more normal life. But COVID-19 and the SARS-CoV-2 virus are still a significant threat in large parts of the world.

30 Sep 2021

The applications of nanomaterials against viral disease

The application of nanomaterials in the diagnosis, prevention, and treatment of viral diseases is reviewed in detail, highlighting areas of significant progress or stagnation from the past few decades.

30 Sep 2021

Diverse vaccine attitudes amongst UK healthcare workers suggest hesitancy may remain after vaccine acceptance

In a recent paper, the phenomenon of vaccine hesitancy is further explored amongst UK healthcare workers.

30 Sep 2021

ACTG to present data highlighting a new therapeutic for COVID-19 at the virtual IDWeek 2021

The AIDS Clinical Trials Group (ACTG), the largest global HIV research network, which recently expanded its focus to include evaluating outpatient treatment for COVID-19, today announced that Teresa H. Evering, M.D., M.S., a co-lead investigator (with Eric S. Daar, M.D.) for BRII-196/BRII-198 in the ACTIV-2 study of Outpatient Monoclonal Antibodies and Other Therapies, will present data for the monoclonal antibody combination at the virtual IDWeek 2021 conference, taking place September 29 – October 3, 2021.

30 Sep 2021

SARS-CoV-2 infection aided by antibody-dependent enhancement

The coronavirus disease 2019 (COVID-19) pandemic has raised concerns about the detrimental effects of antibodies. Antibody-dependent enhancement (ADE) of infection is one of the biggest concerns in terms of not only the antibody reaction to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) upon reinfection with the virus but also the reaction to COVID-19 vaccines.

30 Sep 2021

Instrument to measure risk of reverse zoonotic SARS-CoV-2 transmission events from humans to animals

A new study published on the medRxiv* preprint server presents a standardized survey instrument for evaluating risk factors associated with bidirectional zoonotic transmission of SARS-CoV-2 and pathogens. The instrument is particularly focused on settings where humans and animals share close contact.

30 Sep 2021

SARS News and Research

Comparison of Pfizer, Moderna, J&J, AZ vaccines for neutralization titer, against Delta and other variants

New approach reveals ‘protein partners’ that may contribute to unusual pathologies of COVID-19

Moderna vaccine reduced viral load and protected against SARS-CoV-2 variants in new phase 3 trial

Non-severe COVID-19 may elicit more durable memory B cell response than severe COVID-19

University of Oxford and Oracle's Global Pathogen Analysis System helping researchers to combat COVID-19

Early-stage interaction of monocytes with SARS-CoV-2-infected epithelial cell decides COVID-19 severity

Pediatric transplant recipients mount a more robust immune response after two COVID-19 vaccine doses

Rise of the Delta variant increases COVID-19 hospitalizations among unvaccinated pregnant women

The connection between age and virulence of SARS-CoV-2 variants of concern

SARS-CoV-2 nucleocapsid antigen as a possible COVID-19 severity marker

New drug combination effectively suppresses SARS-CoV-2 infection

The applications of nanomaterials against viral disease

Diverse vaccine attitudes amongst UK healthcare workers suggest hesitancy may remain after vaccine acceptance

ACTG to present data highlighting a new therapeutic for COVID-19 at the virtual IDWeek 2021

SARS-CoV-2 infection aided by antibody-dependent enhancement

Instrument to measure risk of reverse zoonotic SARS-CoV-2 transmission events from humans to animals

Scientists describe SARS-CoV-2 uptake in tissue-resident human macrophages enhanced by virus-specific antibodies

Novel framework can predict changes that may increase the infectiousness of SARS-CoV-2

Effect of biologic therapy on COVID-19 in children suffering from rheumatic diseases

Immunocompromised patients show decreased response to SARS-CoV-2 mRNA vaccines

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Latest News